The purpose of this study is to better understand how fat tissue may contribute to asthma in children and young adults with obesity. Researchers will also use the samples to develop and improve laboratory methods for studying fat tissue and to gather preliminary information that may help guide future research on obesity-related asthma.THIS STUDY IS ENROLLING BY INVITATION ONLY - Children, adolescents, and young adult patients will become potential candidates for the study after their clinical care team determines that appendectomy, cholecystectomy, or bariatric surgery is clinically indicated. Potentially eligible participants may be identified through communication with the clinical care team and/or review of the electronic health record for study eligibility criteria. The study may be introduced to potential participants and their parents/guardians by a member of the research team or by a clinical care provider who normally has access to the individual's confidential information as part of the patient's clinical care.

The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily activities) decline. For each participant, the study will last one and a half years.THIS STUDY IS ENROLLING BY INVITATION ONLY - Potential participants will be recruited by researchers and contacted directly by e-mail, mail, phone, appointment or via clinician referral.

This multicenter, randomized, parallel-arm, double-blind, placebo-controlled Phase 3 umbrella- type master protocol aims to create a framework for simultaneously evaluating the safety and efficacy of multiple pharmacologic agents (interventions) for the treatment of high-risk metabolic dysfunction-associated steatotic liver disease.THIS STUDY IS ENROLLING BY INVITATION ONLY - The study team will identify and invite potential participants with MASLD who may also have been diagnosed with type 2 diabetes mellitus (T2DM) to enroll in the study.

From the patient perspective, stigma and fear of judgment, especially in transplant-adjacent contexts, discourage disclosure of alcohol use and engagement in treatment. Structural challenges, including transportation barriers, unstable housing, caregiving responsibilities, and financial toxicity, further limit participation in treatment. Treatment readiness may also fluctuate with stress, episodes of hepatic decompensation, and social instability, undermining engagement in traditional referral-based models. Collectively, these barriers help explain persistently low treatment rates despite strong evidence that AUD is both treatable and central to improving ALD outcomes. The primary objective of this study is to evaluate the acceptability and multilevel implementation determinants, including individual-level factors and outer setting influences such as socioeconomic context, that shape adoption of and engagement with a digital health intervention for alcohol use disorder among patients with alcohol-associated liver disease.THIS STUDY IS ENROLLING BY INVITATION ONLY - Eligible patients will be identified by review of clinic schedules and will be approached in person either in clinic or in their hosptial room as in inpatient or via a telephone call by a research coordinator who is not involved in their direct clinical care. The coordinator will briefly describe the study and obtain informed consent prior to survey participation. This can be done either in person or remotely.

The purpose of this study is to see if ADAPT, an evidence-based, virtual care program for people living with heart failure, is easy to implement in a regular clinic setting. We also want to see if ADAPT improves quality of life for people with heart failureTHIS STUDY IS ENROLLING BY INVITATION ONLY - Recruitment may take place in-person at the study clinic, if remote methods do not yield adequate enrollment numbers. Flyers will be distributed in the study clinic, and clinicians may introduce the ADAPT program to patients during individual patient visits. If necessary, the research team may present the ADAPT program to patients in the clinic as well. When participants are in person, activities will take place in a private clinic or meeting room to ensure privacy.